GlobalData on MSN5 天
FDA grants ODD to NMD Pharma’s Charcot-Marie-Tooth disease therapy
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NMD Pharma’s oral lead development ...
NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of ...
NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease This is the 2nd ...
Pharmabiz4 天
US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with ...
US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease: Aarhus, Denmark Tuesday, January 7, 2025, 16:00 Hrs [IST] NMD Ph ...
Nature4 天
Neuromuscular disease articles from across Nature Portfolio
Dysferlin-deficient muscular dystrophy is a devastating and untreatable disease. Using Cas9, the authors restored dysferlin in muscle stem cells from patients ex vivo and show proof-of-concept for ...
eLife6 天
SERBP1 interacts with PARP1 and is present in PARylation-dependent protein complexes ...
During the peer-review process the editor and reviewers write an eLife assessment that summarises the significance of the findings reported in the article (on a scale ranging from landmark to useful) ...
Nature5 天
Editors & Editorial Board
Guy joined Scientific Data in October 2021. Prior to that he was the Executive Editor for Data at the Royal Society of Chemistry with responsibility for managing chemical databases and setting ...